Even though the expression of PD-L1 is a crucial predictive factor for the treatment with PD-1/L1 blockade, many recent studies emphasize the importance of deciphering the complex interaction among several types of immune cells and tumor cells to overcome the low rate of therapeutic response. This evidence concerns the gene CD274 and neoplasm.